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Other than being present at the surface of red blood cells, the antigens of the ABO blood group system are
efficiently expressed by a variety of human cells and tissues. Several studies recently described the involvement of
the ABO blood group in the pathogenesis of many human disorders, including cardiovascular disease and cancer,
so that its clinical significance extends now beyond the traditional boundaries of transfusion medicine. In a large
cohort study recently published in BMC Medicine and including over 50,000 subjects, Etemadi and colleagues
reported that nearly 6% of total deaths and as many as 9% of cardiovascular deaths could be attributed to having
non-O blood groups, a condition that was also found to be associated with increased risk of gastric cancer.
In this commentary, the clinical implications of ABO blood groups are critically discussed and a possible common
pathogenic mechanism involving the von Willebrand factor is described.
Please see related article http://dx.doi.org/10.1186/s12916-014-0237-8.
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The antigens of the ABO blood group system (i.e., A, B,
and H antigens), discovered more than one century ago
[1], are complex carbohydrate molecules expressed on
the extracellular surface of red blood cell membranes
[2]. The A and B alleles encode slightly different gly-
cosyltransferases that add N-acetylgalactosamine and
D-galactose to a common precursor side chain, the H
determinant, which is then converted into A- or B-
antigens, respectively (Figure 1). The O alleles do not
encode a functional enzyme, so that OO carriers lack
these transferase enzymes and express the unaltered
H structure, with a solitary terminal fucose moiety at-
tached to the precursor oligosaccharide chain, which
represents the phenotypic marker of the O blood group
[3]. In addition to the expression on red blood cell
surfaces, the ABO antigens are also present in a variety
of human cells and tissues, including epithelium, sen-
sory neurons, platelets, and vascular endothelium [4,5].
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itional boundaries of immunohematology and transfusion
medicine, wherein this antigen system is seemingly in-
volved in the pathophysiology of a wide range of human
diseases, the most important being represented by cancers
and infectious and cardiovascular disorders [6-9].
Discussion
A number of studies conducted in the past 50 years have
consistently described the existence of an association be-
tween ABO blood type and cardiovascular disease [10-12].
In particular, a recent systematic review and meta-analysis
documented that having a non-O blood group carries an
approximately two-fold increased risk of venous throm-
bosis [10]. A weaker but still significant association was
found in another systematic review conducted by the
same group of authors between non-O blood type and
arterial thrombosis (odds ratio [OR] of 1.28 for myocar-
dial infarction and 1.17 for ischemic stroke) [11]. In addi-
tion to the effect of the ABO blood group on low-density
lipoprotein and total serum cholesterol levels [13], the
leading underlying mechanism that has been put forward
to explain this association involves the profound influence
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Figure 1 The intriguing relationship between ABO blood group system, von Willebrand factor (VWF), cancer and cardiovascular disease.
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consequently, on coagulation factor VIII (FVIII) plasma
levels, which are both well recognized prothrombotic
risk factors [14]. Indeed, it is now clearly acknowledged
that individuals of non-O blood group status have
plasma levels of both VWF and FVIII that are approxi-
mately 25% higher than O blood group subjects [15].
The molecular basis of this phenomenon has been pre-
cisely identified with the presence of ABH antigenic
structures on circulating VWF, which modulate the activ-
ity of this multifunctional protein through different de-
grees of glycosylation [12].
Another interesting field that has been extensively
studied over the past five decades is that of the associ-
ation between ABO blood group types and cancer [8,9].
The most consistent association has been found with
pancreatic and gastric cancers [8]. For instance, in the
Nurses’ Health Study and Health Professionals Follow-
up Study, Wolpin et al. [16] found that participants withblood groups A, AB, or B were more likely to develop pan-
creatic cancer compared with those with blood group O
(adjusted hazard ratio [HR]: 1.44; 95% CI: 1.14–1.82). The
higher prevalence of blood group A in patients with
gastric cancer formerly observed by several studies [9]
has also been recently confirmed in a large prospective
population-based study involving more than one million
of Scandinavian blood donors followed for up to 35
years [17]. The strength of this association was similar
to that previously reported (OR: 1.20; 95% CI: 1.02–1.42).
Although the underlying mechanisms linking the ABO
blood group system and cancer are still largely unknown,
one plausible explanation involves the ABO blood group-
driven regulation of circulating levels of several proinflam-
matory and adhesion molecules (i.e., soluble E-selectin,
P-selectin, and intercellular adhesion molecule-1), which
play a key role in the tumorigenesis process [9]. Moreover,
the recent discovery that VWF is an important modula-
tor of angiogenesis and apoptosis provides an alternative,
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nisms by which non-O blood group influences the onset
of cardiovascular and neoplastic diseases (Figure 1) [18].
A significant advance in this field has now been provided
by the Golestan Cohort Study, recently published in BMC
Medicine [19]. This large epidemiological trial analyzed
the association between ABO blood groups and overall
and cause-specific mortality in over 50,000 people recrui-
ted between 2004 and 2008. Notably, the authors found
that non-O blood groups were associated with a signi-
ficantly increased risk of total death (HR: 1.09; 95% CI:
1.01–1.17) and mortality for cardiovascular disease (HR:
1.15; 95% CI: 1.03–1.27). Although no significant associ-
ation was found with ABO-related cancer mortality, an
aspect that was investigated for the first time in this
study, an increased risk of developing gastric cancers
was still observed in individuals with blood groups A
and B. This latter finding is particular intriguing, and is
also in keeping with the results from another recent
study conducted by our group, in which a negative as-
sociation between B blood group and life expectancy in
a large cohort (n = 28,129) of subjects was found [20].
Although the analysis was only limited to overall mor-
tality in our study, this evidence may be attributable to
the association between B blood type and some aging
associated conditions, including neurological and neo-
plastic disorders. Although additional research is needed
to corroborate these preliminary findings, the attractive
data that have emerged from these studies raise a new and
intriguing scenario linking the ABO blood group with
cardiovascular disease and cancer (Figure 1).Conclusions
Despite being studied for more than half a century, the
complex interplay between the ABO blood group system
and human health is far from being definitely elucidated.
In particular, if the association between non-O blood
type and cardiovascular disease mortality is confirmed
by further trials like that recently published by Etemadi
et al. [19], non-O blood group status may be included
in cardiovascular risk scores to better estimate the in-
dividual thrombotic risk profile. Further experimental
studies are also needed to unravel the molecular mecha-
nisms linking ABO blood type, VWF, and cancer develop-
ment. Intuitively appealing, ABO blood typing may hence
become part of a multifaceted strategy for cancer risk
assessment.
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